title: Studies on anabolic steroids. V. Sequential reduction of methandienone and structurally related steroid A-ring substituents in humans: gas chromatographic-mass spectrometric study of the corresponding urinary metabolites.
abstract: The biotransformation of methandienone (17 beta-hydroxy-17 alpha-methylandrosta-1,4-dien-3-one) in human adults, more particularly the sequential reduction of its A-ring substituents, was investigated by gas chromatography-mass spectrometry. Two pairs of 17-epimeric tetrahydro diols resulting from the stereoselective reduction of the delta 4- and 3-oxo groups and of the delta 1-function were characterized. The major diols were 17 alpha-methyl-5 alpha-androstane-3 alpha,17 beta-diol and 17 alpha-methyl-5 beta-androstane-3 alpha,17 beta-diol, which were both excreted in the conjugate fraction in a 1:3.8 ratio. The immediate metabolic precursors of the 5 beta-diol, namely 17 beta-hydroxy-17 alpha-methyl-5 beta-androsta-1-en-3-one and 17 alpha-methyl-5 beta-androsta-1-en-3 alpha,17 beta diol and their corresponding 17-epimers, were also identified in post-administration urine samples. These data indicated that reduction of methandienone A-ring substituents proceeds according to the sequence. delta 4-, 3-oxo- and delta 1-. The A-ring reduction products of the structurally related steroids mestanolone, 17 alpha-methyltestosterone and oxymethone were also characterized and provided further analytical and metabolic evidence supporting the proposed route of methandienone A-ring reduction. It was also demonstrated using synthetic 17 beta-sulfate conjugates of methandienone and 17 alpha-methyltestosterone that their corresponding 17-epimers are formed by nucleophilic substitution by water of the labile sulfate moiety. The steroidal metabolites were identified on the basis of their characteristic mass spectral features and by comparison with authentic reference standards. Metabolic pathways accounting for the occurrence of the metabolites of interest in post-administration urine samples are proposed.
authors.affiliation: Institut National de la Recherche Scientifique, INRS-Santé, Université du Québec, Point Claire, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Massé
authors.forename: H G
authors.initials: HG
authors.lastname: Bi
authors.forename: C
authors.initials: C
authors.lastname: Ayotte
authors.forename: P
authors.initials: P
authors.lastname: Du
authors.forename: H
authors.initials: H
authors.lastname: Gélinas
authors.forename: R
authors.initials: R
authors.lastname: Dugal
mesh_terms: D000328:Adult; D045930:Anabolic Agents / Q000032:analysis*; D013196:Dihydrotestosterone / Q000031:analogs & derivatives / Q000032:analysis / Q000652:urine; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007202:Indicators and Reagents; D008297:Male; D008696:Methandrostenolone / Q000032:analysis* / Q000737:chemistry / Q000652:urine; D008777:Methyltestosterone / Q000652:urine; D008954:Models, Biological; D010084:Oxidation-Reduction; D010110:Oxymetholone / Q000032:analysis / Q000652:urine; D013237:Stereoisomerism
chemical_list: D045930:Anabolic Agents; D007202:Indicators and Reagents; D013196:Dihydrotestosterone; D008696:Methandrostenolone; D010110:Oxymetholone; C008376:mestanolone; D008777:Methyltestosterone